{
  "report_rows": [
    {
      "kpi": "Q2 2026 total revenue",
      "prediction": "BEAT",
      "answer": "pred ~$7.49B vs. cons $7.40B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Yeztugo sales",
      "prediction": "BEAT",
      "answer": "pred ~$245M vs. cons $225M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Biktarvy sales",
      "prediction": "BEAT",
      "answer": "pred ~$3.76B vs. cons $3.70B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 total product-sales guidance midpoint",
      "prediction": "BETTER",
      "answer": "guide ~$30.4B vs. cons $30.3B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Yeztugo sales guidance",
      "prediction": "BETTER",
      "answer": "guide ~$1.10B vs. cons $1.05B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 underlying non-GAAP EPS excluding transaction effects",
      "prediction": "LOWER",
      "answer": "guide ~$8.65 vs. cons $8.75 (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.1,
  "day5_path": "FADE",
  "day5_rationale": "Initial upside from Yeztugo, Biktarvy and the product-sales raise fades as unchanged underlying EPS guidance versus ~$8.75 consensus implies higher second-half launch and acquired-pipeline spending; the predicted 5-day residual is ~+1.1% versus a ~+2.5% day-1 residual.",
  "day5_confidence": "MEDIUM"
}